CRC 12071: An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC)
- Type of Study
- Cancer (Oncology) - Lung
- Location
- Swedish Cancer Institute
- Short Description
Purpose: The purpose of the study is to compare the change in tumor size, and overall survival of BMS-936558 as compared with Docetaxel in subjects with squamous cell non-small cell lung cancer (NSCLC), after failure of prior platinum-based chemotherapy.
- Status
- Open to Enrollment
- Principal Investigator
- Howard (Jack) West, M.D.
- Eligibility Notes
• Subjects with histologically or cytologically-documented squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent disease following radiation therapy or surgical resection
• Disease recurrence or progression during/after one prior platinum-containing chemotherapy regimen for advanced or metastatic disease
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
• No subjects with carcinomatous meningitis
• No subjects with active, known or suspected autoimmune disease, or subjects with interstitial lung disease
• No prior therapy with anti-Programmed death-1 (PD-1), anti-Programmed cell death ligand 1 (PD-L1), anti-Programmed cell death ligand 2 (PD-L2), anti-CD137, or anti-Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• No prior treatment on the first line study CA184104 first line NSCLC study
• No prior treatment with docetaxel- More Info Link
- Additional information about the study summary and eligibility criteria may be viewed on the U.S. National Institutes of Health (NIH) website.
- Phone
- (206) 215-3086
- CancerResearch@swedish.org
